Vir Biotechnology price to free cash flow VIR
Market value divided by free cash flow over the last twelve months, since 2022.
- Today, Nov 2, 2026
- n/m
- not a meaningful number
- Last meaningful
- 2.0×
- Aug 2023
- Peer median
- 30.3×
Vir Biotechnology's price to free cash flow is not a meaningful number today: free cash flow over the last twelve months was zero, negative or not reported.
It was last meaningful in Aug 2023, at 2.0×.
Price to free cash flow over time
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2023 | 2.0× | 1.9× | 3.9× |
| 2022 | 2.1× | 1.8× | 7.2× |
Against its peers
Companies in Biotechnology nearest Vir Biotechnology's size, closest first, today.
| Company | Price to free cash flow |
|---|---|
| VIRVir Biotechnology | n/m |
| VCELVericel | 33.6× |
| ADMAAdma Biologics | 21.3× |
| MGTXMeiraGTx | 85.5× |
| KRYSKrystal Biotech | 34.0× |
| RGENRepligen | 87.2× |
| TECHBIO-TECHNE | 43.3× |
| HALOHalozyme Therapeutics | 18.2× |
| NBIXNeurocrine Biosciences | 17.0× |
| PLXProtalix BioTherapeutics | 26.9× |
| EXELExelixis | 14.8× |
| Peer median | 30.3× |
What the price to free cash flow tells you
Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.
Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.
More on Vir Biotechnology
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.